Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Anthony L. Cunningham, Himal Lal, Martina Kovac, +28

New England Journal of Medicine

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Alemnew F. Dagnew, Osman İlhan, Won Sik Lee, +75

The Lancet Infectious Diseases

VaccinationVaccine SafetyVaccinologyVaccine DevelopmentMedicine +9

Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study

Roman Chlíbek, Jan Smetana, Karlis Pauksens, +7

Vaccine

VaccinologyVaccinationVaccine SafetyVaccine DevelopmentVaccine Research +7

Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults

Roman Chlíbek, Karlis Pauksens, Lars Rombo, +7

Vaccine

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

Céline Boutry, Andrew Hastie, Javier Díez‐Domingo, +38

Clinical Infectious Diseases

Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study

Helena H. Askling, Lars Rombo, Ronald van Vollenhoven, +5

Travel Medicine and Infectious Disease

Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults

Tino F. Schwarz, Stéphanie Volpe, Grégory Catteau, +12

Human Vaccines & Immunotherapeutics

Cross-Protective Capacity of Japanese Encephalitis (JE) Vaccines Against Circulating Heterologous JE Virus Genotypes

Elina Erra, Helena Hervius Askling, Sutee Yoksan, +6

Clinical Infectious Diseases

Hepatitis A Risk in Travelers

Helena Hervius Askling, Lars Rombo, Yvonne Andersson, +2

Journal of Travel Medicine

Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group

Tobias Svensson, Magdalena Kättström, Ylva Hammarlund, +7

Vaccine

VaccinationPneumococcal Conjugate VaccineMedicineVaccine TargetImmunology +9